Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Castle Biosciences, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.361 via question and answer session. I would like to turn the call over to Camilla Zuccaro, 00:00:04.361 -- 00:00:08.270 Vice President of Investor Relations and Corporate Affairs. 00:00:08.270 -- 00:00:09.774 Please go ahead. 00:00:09.774 -- 00:00:12.560 Thank you, operator. Good afternoon, everyone. 00:00:12.560 -- 00:00:17.902 Welcome to Castle Bioscience's first quarter 2025 results conference call. 00:00:17.902 -- 00:00:23.688 Joining me today are CASEL's founder, president, and chief executive officer, Derek Massold, 00:00:23.688 -- 00:00:28.773 chief financial officer, Frank Stokes, and senior vice president, medical, 00:00:28.773 -- 00:00:34.499 Dr. Matthew Goldberg, board certified dermatologist and dermatopathologist. 00:00:34.499 -- 00:00:40.085 Information recorded on this call speaks only as of today, May 5th, 2025. 00:00:40.085 -- 00:00:44.550 Therefore, if you are listening to the replay or reading this transcript of this call, 00:00:44.550 -- 00:00:48.277 any time-sensitive information may no longer be accurate. 00:00:48.277 -- 00:00:52.883 A recording of today's call will be available on the Investor Relations page of the company's 00:00:52.883 -- 00:00:57.769 website for approximately three weeks following the conclusion of the call. 00:00:57.769 -- 00:01:01.775 Before we begin, I would like to remind you that some of the statements made today will 00:01:01.775 -- 00:01:06.381 contain forward-looking statements within the meaning of the Private Securities Litigation 00:01:06.381 -- 00:01:09.134 Reform Act of 1995. 00:01:09.134 -- 00:01:13.260 These forward-looking statements include, but are not limited to, statements about our 00:01:13.260 -- 00:01:18.287 financial outlook, TAM, intended use populations, and similar ...